Canada: Federal Court Finds Health Canada Liable To Apotex In Tort But Apotex Required To Mitigate

Last Updated: December 17 2014
Article by Junyi Chen

On November 18, 2014, Justice Hughes of the Federal Court (Court) issued his ruling in Apotex Inc v Canada, 2014 FC 1087, finding Health Canada (HC) liable for damages to Apotex in tort (namely, for misfeasance in public office and negligence) due to the facts surrounding a 7-year delay in issuing a Notice of Compliance (NOC) to Apotex in respect of Apo-Trazad (trazodone). However, Justice Hughes also found that Apotex was required to mitigate its damages. HC was also held liable for breach of a settlement agreement, but this cause of action failed for being time-barred.

In 1998, Apotex commenced this action for damages, including punitive damages, on the grounds of negligence, breach of a settlement agreement, misfeasance in public office and misrepresentation (negligent, fraudulent or innocent). HC defended, asserting that Apotex's claims were time-barred, that Apotex had repudiated the settlement, that there was no duty of care owed, and that Apotex failed to mitigate its damages.

The issue at trial was whether Apotex was entitled to damages for HC's failure to issue a NOC to Apotex in respect of its Apo-Trazad for seven years, a delay which allegedly caused two competitors to beat Apotex to market with their own generic trazodone products.


On January 25, 1988, Apotex filed a regulatory submission for Apo-Trazad to the Health Protection Branch (HPB) within HC. Apotex's submission relied on a US reference product. At that time, HC did not have a clear policy or guidelines on the ability to use a foreign reference product to obtain generic drug approval. It did not accept Apotex's submission and required Apotex to use a Canadian reference product unless the US reference product could be "conclusively proven to be identical" to the Canadian product.

In August 1990, Apotex brought a judicial review application to compel the Minister to review its submission without requiring the use of a Canadian reference product and issue an NOC. The parties reached a settlement agreement on November 26, 1990 and the application was discontinued. According to the settlement agreement, the HPB was prepared to consider evidence to establish equivalency between Canadian and US reference standards for the purposes of a comparative bioavailability study.

Apotex submitted further bioavailability data to establish equivalency pursuant to the settlement agreement; however, HPB continued to insist on identicality.

In July 1991, Apotex brought a second judicial review application, which was dismissed by Justice MacKay in January 1993, holding that HPB's actions were not "patently unreasonable".

Seven years after filing its original submission, on February 28, 1995, Apotex received its NOC for Apo-Trazad.

Apotex's Tort Claims

Misfeasance in Public Office

Justice Hughes held that there were two elements to the tort of public misfeasance: (1) a deliberate unlawful conduct in the exercise of a public function; and (2) an awareness that the conduct is unlawful and would likely injure the plaintiff. He found that both elements were satisfied in this case:

"i Upon entering into the Settlement Agreement with Apotex, HPB acted in bad faith by engaging in a deliberate exercise of conducting its examination of Apotex's submissions on the basis of identicality, notwithstanding its undertaking to do otherwise; and

ii HPB were quite aware that a delay or refusal to accept Apotex's submissions would be likely to injure Apotex, given Dr. Sherman's repeated warnings to HPB of the same."


Justice Hughes found that once HPB entered into the settlement agreement with Apotex, it owed a duty of care towards Apotex and their breach of this duty caused Apotex's loss. He also found that Apotex's damages were not remote, as it was reasonably foreseeable that delaying issuance of the NOC would cause Apotex damages in lost sales and prevent Apotex from being the first in the market. He concluded that the HPB's refusal to adhere to the equivalency standard set out in the settlement agreement constituted negligence.

Breach of Settlement Agreement and Limitation Period

Justice Hughes agreed with Apotex that the HPB misled Apotex by stating in the settlement agreement that it would apply an equivalency standard, when in fact, it would not. However, he found that Apotex's claim for breach of the settlement agreement was time-barred. He concluded that HPB had breached the settlement agreement almost immediately following its execution on November 26, 1990; therefore, Apotex would have had to bring this claim before November 1996.

Damages and Mitigation

Justice Hughes held that Apotex's entitlement to damages would commence at a date when it reasonably could have expected to receive the NOC (November 26, 1991) and end on the date when it actually received the NOC; however, Apotex was required to mitigate its damages as-of July 2, 1991 (the date that Apotex wrote to Health Canada indicating that it would mitigate damages by conducting further testing using another drug product). Therefore, damages are properly calculated starting on November 26, 1991, when Apotex could have reasonably expected to receive the NOC, and ending in mid-November, 1992, the date the NOC would have been received if Apotex had taken steps to mitigate.

Regarding the issue of mitigation, Justice Hughes recognized that Apotex was using its Apo-Trazad submission as a test-case and noted

"... the Court should not view the question of damages and mitigation from the point of view of a party wanting to make a point. Here, we are dealing with economic circumstances, loss by one party, and payment out of the public purse by another. Damages here are not an award for winning a point, damages are to provide reasonable compensation for unavoidable loss. The reasonable person thinks in terms of economics, not principle."

For more commentary, see

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.